NCT04652518 is a Phase 2 clinical trial of LYT-100 in Covid19, sponsored by PureTech.

Who is sponsoring NCT04652518?

NCT04652518 is sponsored by PureTech.

What drugs are being tested in NCT04652518?

Interventions in NCT04652518: LYT-100, Placebo.

What condition does NCT04652518 study?

NCT04652518 studies Covid19, Post-acute COVID-19 Respiratory Disease.

Is NCT04652518 still recruiting?

NCT04652518 is currently terminated. Last updated 14 February 2024.

Last reviewed 2024-02-14 · How we verify

NCT04652518

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LYT-100 in Post-acute COVID-19 Respiratory Disease

Terminated Phase 2 Last updated 14 February 2024

What this trial tests

Phase 2 trial testing LYT-100 in Covid19 in 185 participants. Terminated before completion.

Timeline

11 December 2020

Primary endpoint
28 June 2022

18 July 2022

Quick facts

Lead sponsor	PureTech
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	185
Start date	11 December 2020
Primary completion	28 June 2022
Estimated completion	18 July 2022
Sites	31 locations across Ukraine, United Kingdom, Moldova, Philippines, Argentina, Romania, United States, Brazil

Drugs / interventions tested

LYT-100 — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →
Post-acute COVID-19 Respiratory Disease — all drugs for Post-acute COVID-19 Respiratory Disease →

Sponsor

PureTech — full company profile →

Who can join

Adults 18 to 80, any sex, with Covid19 or Post-acute COVID-19 Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Post-acute COVID-19 syndrome.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, et al · · 2021 · cited 3355× · PMID 33753937 · DOI 10.1038/s41591-021-01283-z
Deuterium in drug discovery: progress, opportunities and challenges.
Di Martino RMC, Maxwell BD, Pirali T. · · 2023 · cited 228× · PMID 37277503 · DOI 10.1038/s41573-023-00703-8
Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19.
D'Agnillo F, Walters KA, Xiao Y, Sheng ZM, et al · · 2021 · cited 195× · PMID 34648357 · DOI 10.1126/scitranslmed.abj7790
Lung Fibrosis after COVID-19: Treatment Prospects.
Bazdyrev E, Rusina P, Panova M, Novikov F, et al · · 2021 · cited 123× · PMID 34451904 · DOI 10.3390/ph14080807
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative.
Bonilla H, Peluso MJ, Rodgers K, Aberg JA, et al · · 2023 · cited 72× · PMID 36969241 · DOI 10.3389/fimmu.2023.1129459
Clinical trials on the pharmacological treatment of long COVID: A systematic review.
Chee YJ, Fan BE, Young BE, Dalan R, et al · · 2023 · cited 55× · PMID 36349400 · DOI 10.1002/jmv.28289
A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International Clinical Trials Platform.
Ashraf N, Abou Shaar B, Taha RM, Arabi TZ, et al · · 2023 · cited 35× · PMID 36642173 · DOI 10.1016/j.cmi.2023.01.007
Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?
Zheng Z, Peng F, Zhou Y. · · 2023 · cited 31× · PMID 37388822 · DOI 10.1016/j.pccm.2022.12.002

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other PureTech trials

Trials by the same sponsor.

NCT06717100 — Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib · Phase 1 · completed
NCT05321420 — LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · active not recruiting
NCT05129865 — LYT-300 in Healthy Volunteers · Phase 1, PHASE2 · completed
NCT07456800 — PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects · Phase 1 · completed
NCT04666688 — LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04652518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PureTech
Last refreshed: 14 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04652518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing